Related Experiment Video
Updated: Jun 6, 2026
08:49
A 3D Organotypic Melanoma Spheroid Skin Model
Published on: May 18, 2018
Advances in targeted therapy for melanoma
Philip Friedlander1, F Stephen Hodi
1Instructor of Medicine, Department of Medical Oncology at Dana Farber Cancer Institute in Boston, Massachusetts 02115, USA. pfriedlander@partners.org
Clinical Advances in Hematology & Oncology : H&O
|December 16, 2010
Summary
Metastatic melanoma is aggressive, with limited treatment options. Targeted therapies focusing on specific molecular abnormalities, like BRAF, NRAS, or KIT mutations, show promise for improving patient survival.
Area of Science:
- Oncology
- Molecular Biology
- Dermatology
Background:
- Metastatic melanoma is an aggressive cancer with a poor prognosis.
- Current standard treatments offer limited survival benefits.
- No targeted therapies are approved for advanced melanoma.
Purpose of the Study:
- To review advances in targeted treatment strategies for melanoma subgroups.
- To highlight the role of molecular abnormalities in melanoma progression.
- To discuss the potential of pathway-specific inhibitors.
Main Methods:
- Review of current literature on melanoma molecular alterations.
- Analysis of signal transduction pathways involved in melanoma.
- Discussion of clinical investigations for targeted therapies.
Main Results:
- Specific mutations (BRAF, NRAS, KIT) are identified in melanoma subgroups.
- Mitogen-activated protein kinase (MAPK) pathway mutations are common.
- KIT oncogene mutations are prevalent in specific melanoma types.
Conclusions:
- Targeted therapies inhibiting MAPK pathway or KIT are under investigation.
- Personalized treatment based on molecular profiles is crucial.
- Advances in targeted strategies offer hope for advanced melanoma patients.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:30Skin Cancer
Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
02:50Combination Therapies and Personalized Medicine
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
01:24Modified-Release Drug Delivery Systems: Site-Targeted
Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.